Emavusertib hydrochloride is under clinical development by Curis and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Emavusertib hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Emavusertib hydrochloride overview
Emavusertib hydrochloride is under development for the treatment of diffuse large B cell lymphomas, metastatic urothelial cancer, relapsed or refractory follicular lymphoma, myelodysplastic syndrome, chronic lymphocytic leukemia., mantle cell lymphoma, primary CNS lymphoma, secondary CNS lymphoma non-Hodgkin lymphomas such as marginal zone lymphoma, hematologic malignancies, gastric cancer, pancreatic ductal adenocarcinoma, metastatic melanoma, esophageal cancer and adenocarcinoma of the gastroesophageal junction, non-Hodgkin lymphomas such as myelodysplastic syndrome, chronic myelomonocytic leukemia (CMML), chronic myelocytic leukemia (CML, chronic myeloid leukemia). It is a small molecule administered orally. The drug candidate is a triple target inhibitor interleukin-1 receptor-associated kinase-4 (IRAK-4), FLT3 (FMS like tyrosine kinase 3) and CLK (CDC-like kinase). It was also under development for the treatment of rheumatoid arthritis, anemia in myelodysplastic syndromes, relapsed or refractory acute myelocytic leukemia, and Waldenstrom macroglobulinemia.
Curis overview
Curis is a biotechnology company. It is focused on developing innovative cancer treatments. The company’s product pipeline includes emavusertib (CA-4948), an oral IRAK4 inhibitor targeting dysregulated signaling pathways in cancer. Curis is investigating emavusertib in patients with relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes. It is also being tested in combination with azacitidine and venetoclax in the AML Triplet study. Additionally, the company has other programs like Fimepinostat, CA-170, and the outlicensed Erivedge, a Hedgehog pathway antagonist approved for basal cell carcinoma. Curis is headquartered in Lexington, Massachusetts, the US.
For a complete picture of Emavusertib hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
